Combination treatment for advanced esophageal or stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs, sacituzumab tirumotecan and tagitanlimab, for people with advanced esophageal or stomach cancer that has progressed after initial treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced esophageal squamous cell carcinoma or stomach/gastroesophageal junction adenocarcinoma that cannot be removed by surgery or has spread.
- Your cancer progressed after at least one line of treatment that included an anti-PD-1 drug combined with chemotherapy.
- You have not had certain prior treatments, including TROP2-targeted agents or topoisomerase I inhibitors.
- You are in generally good health (able to care for yourself) and have adequate organ function.
- You do not have active infections like hepatitis B, hepatitis C, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medications (Sac-TMT and fruquintinib) as a second-line treatment for advanced stomach cancer. The goal is to see if this combination can help shrink tumors or slow the cancer's growth after a first treatment has stopped working.
This trial tests a new combination of drugs for advanced stomach or gastroesophageal junction cancer that has not been treated before. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs for advanced stomach cancer that has spread or come back. It aims to see if adding an immune therapy and a bacterial extract to standard chemotherapy can help control the cancer better.
This trial tests a combination of two drugs for advanced esophageal cancer that has grown despite earlier treatment. The goal is to see if this combination can help shrink tumors and slow the disease.
This study tests a new combination of two drugs (sacituzumab tirumotecan and another drug) for people with advanced esophageal cancer. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (sacituzumab tirumotecan and tagitanlimab) for people with advanced triple-negative breast cancer that has progressed after earlier treatments. The goal is to see if this combination can help control the cancer.
Hear when a new ESCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.